SK1012004A3 - Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka - Google Patents

Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka Download PDF

Info

Publication number: SK1012004A3
Authority: SK; Slovakia
Prior art keywords: azithromycin; dose; medicament; treatment; range
Prior art date: 2001-08-21

Application number

SK101-2004A

Other languages

English (en)

Slovak (sk)

Inventor

Michael William Dunne

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-21

Filing date

2002-07-31

Publication date

2005-04-01

2002-07-31 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2005-04-01 Publication of SK1012004A3 publication Critical patent/SK1012004A3/sk

Links

229960004099 azithromycin Drugs 0.000 title claims abstract description 46
MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 title claims abstract description 46
206010057190 Respiratory tract infections Diseases 0.000 title claims abstract description 17
239000003814 drug Substances 0.000 title claims description 15
238000004519 manufacturing process Methods 0.000 title claims description 8
230000037396 body weight Effects 0.000 claims description 13
208000022760 infectious otitis media Diseases 0.000 claims description 10
239000007788 liquid Substances 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 4
238000000034 method Methods 0.000 abstract description 8
208000015181 infectious disease Diseases 0.000 description 16
244000052769 pathogen Species 0.000 description 10
241000606768 Haemophilus influenzae Species 0.000 description 8
208000005141 Otitis Diseases 0.000 description 6
208000019258 ear infection Diseases 0.000 description 6
230000001154 acute effect Effects 0.000 description 5
230000001717 pathogenic effect Effects 0.000 description 5
241000699694 Gerbillinae Species 0.000 description 4
241000588655 Moraxella catarrhalis Species 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
206010033078 Otitis media Diseases 0.000 description 3
230000003115 biocidal effect Effects 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
230000000813 microbial effect Effects 0.000 description 3
238000012360 testing method Methods 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
241000194032 Enterococcus faecalis Species 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000193996 Streptococcus pyogenes Species 0.000 description 2
238000011161 development Methods 0.000 description 2
210000000959 ear middle Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008029 eradication Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
210000003454 tympanic membrane Anatomy 0.000 description 2
VQEMDSRIOVZAOM-UHFFFAOYSA-N 4-(4-methylsulfonylphenyl)-1,3-thiazol-2-amine Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CSC(N)=N1 VQEMDSRIOVZAOM-UHFFFAOYSA-N 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
206010008326 Cervicitis gonococcal Diseases 0.000 description 1
241000606153 Chlamydia trachomatis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
229930006677 Erythromycin A Natural products 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
206010040007 Sense of oppression Diseases 0.000 description 1
201000010439 acute gonococcal cervicitis Diseases 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229960004924 azithromycin dihydrate Drugs 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000032625 disorder of ear Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
239000012530 fluid Substances 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
208000028320 gonococcal cervicitis Diseases 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
210000004969 inflammatory cell Anatomy 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000003120 macrolide antibiotic agent Substances 0.000 description 1
206010027175 memory impairment Diseases 0.000 description 1
150000004682 monohydrates Chemical class 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
208000023504 respiratory system disease Diseases 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000011125 single therapy Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000003826 tablet Substances 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

SK101-2004A 2001-08-21 2002-07-31 Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka SK1012004A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31386701P	2001-08-21	2001-08-21
PCT/IB2002/003076 WO2003018031A2 (fr)	2001-08-21	2002-07-31	Azithromycine unidose

Publications (1)

Publication Number	Publication Date
SK1012004A3 true SK1012004A3 (sk)	2005-04-01

Family

ID=23217490

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK101-2004A SK1012004A3 (sk)	2001-08-21	2002-07-31	Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka

Country Status (25)

Country	Link
US (3)	US20030148964A1 (fr)
EP (1)	EP1418924A2 (fr)
JP (1)	JP2005501862A (fr)
KR (1)	KR20040032942A (fr)
AP (1)	AP1729A (fr)
BG (1)	BG108537A (fr)
BR (1)	BR0211830A (fr)
CA (1)	CA2458135A1 (fr)
CZ (1)	CZ2004232A3 (fr)
EA (1)	EA200400214A1 (fr)
EC (1)	ECSP044985A (fr)
GE (1)	GEP20063812B (fr)
HR (1)	HRP20040163A2 (fr)
HU (1)	HUP0401332A2 (fr)
IL (1)	IL159585A0 (fr)
IS (1)	IS7092A (fr)
MA (1)	MA27059A1 (fr)
MX (1)	MXPA04001605A (fr)
OA (1)	OA12845A (fr)
PL (1)	PL367888A1 (fr)
SK (1)	SK1012004A3 (fr)
TN (1)	TNSN04035A1 (fr)
WO (1)	WO2003018031A2 (fr)
YU (1)	YU8804A (fr)
ZA (1)	ZA200400804B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7572773B2 (en) *	2003-07-24	2009-08-11	Pliva Hrvatska D.O.O.	Single dose fast dissolving azithromycin
CN1889932A (zh)	2003-12-04	2007-01-03	辉瑞产品公司	制备药用多颗粒的方法
WO2005053651A1 (fr)	2003-12-04	2005-06-16	Pfizer Products Inc.	Compositions multiparticulaires a stabilite amelioree
WO2005053656A1 (fr)	2003-12-04	2005-06-16	Pfizer Products Inc.	Procede d'atomisation/congelation faisant appel a une extrudeuse pour la preparation de compositions medicamenteuses cristallines multiparticulaires contenant de preference un poloxamere et un glyceride
US6984403B2 (en)	2003-12-04	2006-01-10	Pfizer Inc.	Azithromycin dosage forms with reduced side effects
US20060116336A1 (en) *	2004-03-17	2006-06-01	American Pharmaceutical Partners, Inc.	Lyophilized azithromycin formulation
US7468428B2 (en)	2004-03-17	2008-12-23	App Pharmaceuticals, Llc	Lyophilized azithromycin formulation
WO2007067520A2 (fr)	2005-12-08	2007-06-14	Transave, Inc.	Compositions a base de lipide d'anti-infectieux pour traiter des infections pulmonaires et procedes d'utilisation de celles-ci
US9119783B2 (en)	2007-05-07	2015-09-01	Insmed Incorporated	Method of treating pulmonary disorders with liposomal amikacin formulations
US20090005326A1 (en) *	2007-06-26	2009-01-01	Idexx Laboratories, Inc.	Single dose roxithromycin
US20090197956A1 (en) *	2008-02-04	2009-08-06	Arbor Pharmaceuticals, Inc.	Treatment of acute otitis media with xylitol and n-acetylcysteine
US20110105421A1 (en) *	2008-03-14	2011-05-05	The Florida International University Board Of Trustees	Ellagitannins as inhibitors of bacterial quorum sensing
US20130156803A1 (en)	2011-06-04	2013-06-20	Rochester General Hospital Research Institute	Compositions and methods related to p6
BR112015012351A8 (pt)	2012-11-29	2019-10-01	Insmed Inc	composição de antibiótico de glicopeptídeo à base de lipídeo estabilizado e uso de um componente lipídico, um componente de antibiótico de glicopeptídeo e um aminoácido ou derivado do mesmo
EP4393491A3 (fr)	2014-05-15	2024-07-24	Insmed Incorporated	Méthodes de traitement d'infections pulmonaires mycobactériennes non-tuberculeuses
JP7460534B2 (ja)	2018-03-30	2024-04-02	インスメッドインコーポレイテッド	リポソーム医薬品の連続製造方法
EP4103725A4 (fr) *	2020-02-14	2024-03-27	Asklepios Biopharmaceutical, Inc.	Procédé de traitement d'une toxicité associée à une thérapie génique avec des antibiotiques

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US53264A (en) *		1866-03-20		Improved ditching-machine
YU43116B (en)	1979-04-02	1989-04-30	Pliva Pharm & Chem Works	Process for preparing 11-aza-4-o-cladinosyl-6-o-desosaminyl-15-ethyl-7,13,14-trihydroxy-3,5,7,9,12,14-hexamethyl-oxacyclopentadecane-2-one(11-aza-10-deox
SI8110592A8 (en)	1981-03-06	1996-06-30	Pliva Pharm & Chem Works	Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof
US4474768A (en)	1982-07-19	1984-10-02	Pfizer Inc.	N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
MX12213A (es)	1987-07-09	1993-05-01	Pfizer	Metodo de preparacion de dihidrato de azitromicina cristalino
WO1989002271A1 (fr)	1987-09-10	1989-03-23	Pfizer	Azithromycine et derives utilises comme agents anti-protozoaires
YU45590A (sh)	1990-03-07	1992-07-20	PLIVA FARMACEVTSKA, KEMIJSKA, PREHRAMBENA I KOZMETIČKA INDUSTRIJA s.p.o.	Novi kompleksi odnosno helati antibiotika s dvovalentnim i/ili trovalentnim metalima i postupci za njihovo dobijanje
TW271400B (fr)	1992-07-30	1996-03-01	Pfizer
WO1994026758A1 (fr)	1993-05-19	1994-11-24	Pfizer Inc.	Intermediaire s'appliquant a l'azithromycine
US5605889A (en)	1994-04-29	1997-02-25	Pfizer Inc.	Method of administering azithromycin
SI9520049A (en)	1994-05-06	1997-12-31	Pfizer	Controlled-release dosage forms of azithromycin
HRP980189B1 (en) *	1998-04-06	2004-04-30	Pliva Pharm & Chem Works	Novel 15-membered lactams ketolides
US6239113B1 (en) *	1999-03-31	2001-05-29	Insite Vision, Incorporated	Topical treatment or prevention of ocular infections
US20040053264A1 (en) *	2002-02-01	2004-03-18	Park Sung Sup	Clinical panel assay using DNA chips

2002
- 2002-07-31 GE GE5411A patent/GEP20063812B/en unknown
- 2002-07-31 BR BR0211830-0A patent/BR0211830A/pt not_active IP Right Cessation
- 2002-07-31 SK SK101-2004A patent/SK1012004A3/sk not_active Application Discontinuation
- 2002-07-31 AP APAP/P/2004/002968A patent/AP1729A/en active
- 2002-07-31 KR KR10-2004-7002492A patent/KR20040032942A/ko not_active Ceased
- 2002-07-31 MX MXPA04001605A patent/MXPA04001605A/es active IP Right Grant
- 2002-07-31 OA OA1200400048A patent/OA12845A/en unknown
- 2002-07-31 JP JP2003522549A patent/JP2005501862A/ja active Pending
- 2002-07-31 IL IL15958502A patent/IL159585A0/xx unknown
- 2002-07-31 PL PL02367888A patent/PL367888A1/xx not_active Application Discontinuation
- 2002-07-31 CZ CZ2004232A patent/CZ2004232A3/cs unknown
- 2002-07-31 WO PCT/IB2002/003076 patent/WO2003018031A2/fr not_active Application Discontinuation
- 2002-07-31 CA CA002458135A patent/CA2458135A1/fr not_active Abandoned
- 2002-07-31 EA EA200400214A patent/EA200400214A1/ru unknown
- 2002-07-31 EP EP02753170A patent/EP1418924A2/fr not_active Withdrawn
- 2002-07-31 YU YU8804A patent/YU8804A/sh unknown
- 2002-07-31 HU HU0401332A patent/HUP0401332A2/hu unknown
- 2002-08-21 US US10/224,903 patent/US20030148964A1/en not_active Abandoned
2003
- 2003-07-25 US US10/628,102 patent/US6987093B2/en not_active Expired - Fee Related
- 2003-12-23 IS IS7092A patent/IS7092A/is unknown
2004
- 2004-01-21 BG BG108537A patent/BG108537A/bg unknown
- 2004-01-30 ZA ZA200400804A patent/ZA200400804B/en unknown
- 2004-02-11 MA MA27523A patent/MA27059A1/fr unknown
- 2004-02-19 HR HR20040163A patent/HRP20040163A2/xx not_active Application Discontinuation
- 2004-02-20 TN TNP2004000035A patent/TNSN04035A1/fr unknown
- 2004-02-20 EC EC2004004985A patent/ECSP044985A/es unknown
2005
- 2005-06-29 US US11/172,012 patent/US7067493B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6987093B2 (en)	2006-01-17
WO2003018031A2 (fr)	2003-03-06
AP1729A (en)	2007-03-26
AP2004002968A0 (en)	2004-03-31
CA2458135A1 (fr)	2003-03-06
BG108537A (bg)	2005-02-28
BR0211830A (pt)	2004-09-08
YU8804A (sh)	2006-08-17
MA27059A1 (fr)	2004-12-20
US20030148964A1 (en)	2003-08-07
MXPA04001605A (es)	2004-07-08
PL367888A1 (en)	2005-03-07
EA200400214A1 (ru)	2004-06-24
US20040023898A1 (en)	2004-02-05
HRP20040163A2 (en)	2005-02-28
OA12845A (en)	2006-09-15
TNSN04035A1 (fr)	2006-06-01
IL159585A0 (en)	2004-06-01
HUP0401332A2 (hu)	2004-11-29
ECSP044985A (es)	2004-04-28
US7067493B2 (en)	2006-06-27
JP2005501862A (ja)	2005-01-20
WO2003018031A3 (fr)	2003-10-02
US20050250712A1 (en)	2005-11-10
ZA200400804B (en)	2005-05-03
KR20040032942A (ko)	2004-04-17
EP1418924A2 (fr)	2004-05-19
CZ2004232A3 (cs)	2005-10-12
IS7092A (is)	2003-12-23
GEP20063812B (en)	2006-05-10

Legal Events

Date	Code	Title	Description
2010-11-08	FC9A	Refused patent application

Publication	Publication Date	Title
SK1012004A3 (sk)	2005-04-01	Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka
Biondi et al.	1997	Psychological stress, neuroimmunomodulation, and susceptibility to infectious diseases in animals and man: a review
Imran et al.	2021	Trends in the development of remdesivir based inventions against COVID-19 and other disorders: A patent review
KR20090125821A (ko)	2009-12-07	인플루엔자 치료용 조성물 및 키트
CN104023719B (zh)	2017-05-24	戊二酰组胺用于治疗呼吸道疾病的用途
US20230158259A1 (en)	2023-05-25	Products of manufacture and methods for treating, ameliorating or preventing microbial infections
Li et al.	2003	A double-blind, randomized, placebo-controlled multicenter study of oseltamivir phosphate for treatment of influenza infection in China
WO2023165566A1 (fr)	2023-09-07	Médicament pour le traitement et la prévention de maladies associées provoquées par des infections virales, et son utilisation
Tush et al.	1998	Intraventricular quinupristin/dalfopristin for the treatment of vancomycin-resistant Enterococcus faecium shunt infection
US20230111504A1 (en)	2023-04-13	Coronaviridae infection and avermectins
US20060142254A1 (en)	2006-06-29	Antipyretic preparation containing xylitol
US20060210483A1 (en)	2006-09-21	Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20200330487A1 (en)	2020-10-22	Prevention and treatment of flu-type viral infections and related complications
Channa et al.	2006	Effect of ciprofoxacin on growing cartilage in albino rat pups
US11090315B1 (en)	2021-08-17	Prevention and treatment of flu-type viral infections and related complications
US20230030607A1 (en)	2023-02-02	Novel oxygen pulse therapy method for treating COVID19 and viral, bacterial, fungal or parasitic respiratory and other diseases
AU2002313574A1 (en)	2003-03-10	Single dose azithromycin for treating respiratory infections
Fawcett et al.	1976	Allergy to a tetracycline preparation—a case report
US20250120929A1 (en)	2025-04-17	Method of treating virus-associated infection using acetaminophen
Sataloff et al.	1996	Very high-dose streptomycin labyrinthectomy
WO2024129551A1 (fr)	2024-06-20	Forme posologique solide d'un antiviral à petites molécules et ses utilisations
Güris	2000	Treatment and chemoprophylaxis
WO2023052830A2 (fr)	2023-04-06	Prévention et traitement d'infections virales de type grippe et de complications associées
Mattos Filho et al.	2006	Effect of betamethasone and diclofenac sodium on serum and tissue concentration of amoxicillin: in vivo study in rats
US20060057133A1 (en)	2006-03-16	Topical pathogenic-tissue-destroying liquid